Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi study shows benefits of semuloparin

Sanofi study shows benefits of semuloparin

7th June 2011

Sanofi has published data from a new clinical trial which illustrates the benefits its investigational treatment semuloparin can deliver for cancer patients.

The company has presented results from a new phase III study called Save-Onco at the American Society of Clinical Oncology (ASCO) annual meeting, which involved 3,212 patients undergoing a chemotherapy regimen for locally advanced or metastatic solid tumours.

In this trial, semuloparin was able to meet its primary efficacy endpoint by reducing the risk of symptomatic deep-vein thromboembolism, non-fatal pulmonary embolism or venous thromboembolism among patients.

The results presented by Sanofi from Save-Onco have been selected among the Best of ASCO list for 2011, which showcases the conference's most cutting-edge oncology research.

Dr Elias Zerhouni, president for global research and development at Sanofi, said: "Based on these results of Save-Onco we plan to submit semuloparin for regulatory filing in Q3 2011."

Earlier this month, the company also presented data on its new diabetes drug Lyxumia, demonstrating its efficacy as an add-on treatment.ADNFCR-8000103-ID-800569593-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.